JP Patent

JP5826261B2 — 癌に対する使用のためのキナーゼ阻害剤としての2,4−ジアリール置換[1,8]ナフチリジン

Assigned to Merck Patent GmbH · Expires 2015-12-02 · 10y expired

What this patent protects

Patent listed against sodium-oxybate.

Drugs covered by this patent

Patent Metadata

Patent number
JP5826261B2
Jurisdiction
JP
Classification
Expires
2015-12-02
Drug substance claim
No
Drug product claim
No
Assignee
Merck Patent GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.